Related Experiment Video
Updated: May 5, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Momordica charantia L. Confers Multifaceted Protection Against 5-Fluorouracil-Induced Intestinal Injury via
Wen-Ping Jiang1, Jaung-Geng Lin2,3, Atsushi Inose4
1School of Pharmacy, China Medical University, Taichung 404, Taiwan.
Abstract:
Momordica charantia L. (MC), also referred to as bitter gourd or bitter melon, is a Cucurbi taceae plant renowned for its medicinal benefits. 5-Fluorouracil (5-FU) is employed as a frontline chemotherapeutic agent, with its antitumor activity mediated through the inhibition of DNA and RNA synthesis. However, its therapeutic efficacy is often compromised by serious adverse effects, particularly gastrointestinal inflammation. Therefore, this research examined the efficacy of the ethanolic extract of Momordica charantia fruit (EMC) in mitigating 5-FU-induced intestinal mucositis in mice. Mucositis was induced in mice by intraperitoneal administration of 5-FU at 50 mg/kg from experimental days 4 to 7, with EMC administered orally at doses of 125 mg/kg and 250 mg/kg once daily for ten consecutive days. 5-FU exposure resulted in severe intestinal injury, manifested by markedly upregulated inflammation and oxidative stress. EMC treatment significantly reversed these pathophysiological alterations, restoring mucosal architecture and function. Furthermore, EMC effectively reduced the 5-FU-induced release of inflammatory mediators and oxidative stress markers. These results demonstrate that EMC acts as a novel protective modulator of 5-FU-induced mucositis, offering substantial translational potential as an adjunctive supportive therapy in colorectal cancer management.
More Related Videos
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Cancer Prevention
Some...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase